Durveqtix%252525252525252525252525252525252525252525252525252525252525252525252520gene%252525252525252525252525252525252525252525252525252525252525252525252520therapy

# Durveqtix gene therapy ## Overview Durveqtix (prademagen) is a one-time gene therapy for patients with severe (defined as \<20 IU/dL or \<20% of normal) Factor XI deficiency. It is administered as a single intravenous infusion. The mechanism involves delivering a functional *F11* gene to hepatocytes, enabling them to produce Factor XI. ## Primary Indications Treatment of severe Factor XI deficiency in individuals 12 years of age and older. ## Adult Dosing The recommended dose is 1.5 x 10^13 vector genomes (vg) per kilogram of body weight (or 1500 vg/kg) administered as a single intravenous infusion. The maximum dose is not explicitly defined in common prescribing information but is generally guided by the calculated dose based on the patient's weight. ## Pediatric Dosing The recommended dose is 1.5 x 10^13 vector genomes (vg) per kilogram of body weight (or 1500 vg/kg) administered as a single intravenous infusion for patients 12 years of age and older. Dosing for children younger than 12 years of age has not been established. ## Dose Adjustments No dose adjustments are specified based on renal or hepatic impairment. ## Contraindications * Known history of hypersensitivity to the active substance or any excipients. * Patients who have received prior *F11* gene therapy. ## Adverse Effects The most common adverse reactions observed in clinical trials (incidence ≥5%) were headache and injection site reactions. Clinical trials are limited, and other adverse effects may occur. ## Key Drug Interactions No significant drug interactions have been identified in common prescribing information. However, co-administration with immunosuppressants could potentially interfere with Durveqtix efficacy. ## Monitoring * Monitor for signs and symptoms of hypersensitivity reactions during and after infusion. * Baseline and periodic monitoring of Factor XI levels should be performed to assess efficacy and potentially inform management of bleeding events. * Long-term monitoring for potential adverse events, including immune responses, is recommended. ## Clinical Pearls * Durveqtix is a one-time treatment; re-administration is not recommended due to potential immune responses. * Patients should be monitored for any signs of allergic reaction during and after infusion. * The long-term efficacy and safety profile of Durveqtix are still being established. *** **Disclaimer:** This information is intended for healthcare professionals. It is essential to consult the most current prescribing information and relevant guidelines, as product information and clinical practice can evolve. Dose recommendations may vary based on local protocols and individual patient factors.